Abstract:BACKGROUND:To determine the potential value of serum tumor markers in predicting pCR (pathological complete response) during neoadjuvant chemotherapy. MATERIALS AND METHODS:We retrospectively monitored the pro-, mid-, and post- neoadjuvant treatment serum tumor marker concentrations in patients with locally advanced breast cancer (stage II-III) who accepted pre-surgical chemotherapy or chemotherapy in combination with targeted therapy at Fudan University Shanghai Cancer Center between September 2011 and January 2014 and investigated the association of serum tumor marker levels with therapeutic effect. Core needle biopsy samples were assessed using immunohistochemistry (IHC) prior to neoadjuvant treatment to determine hormone receptor, human epidermal growth factor receptor 2(HER2), and proliferation index Ki67 values. In our study, therapeutic response was evaluated by pCR, defined as the disappearance of all invasive cancer cells from excised tissue (including primary lesion and axillary lymph nodes) after completion of chemotherapy. Analysis of variance of repeated measures and receiver operating characteristic (ROC) curves were employed for statistical analysis of the data. RESULTS:A total of 348 patients were recruited in our study after excluding patients with incomplete clinical information. Of these, 106 patients were observed to have acquired pCR status after treatment completion, accounting for approximately 30.5% of study individuals. In addition, 147patients were determined to be Her-2 positive, among whom the pCR rate was 45.6% (69 patients). General linear model analysis (repeated measures analysis of variance) showed that the concentration of cancer antigen (CA) 15-3 increased after neoadjuvant chemotherapy in both pCR and non-pCR groups, and that there were significant differences between the two groups (P=0.008). The areas under the ROC curves (AUCs) of pre-, mid-, and post-treatment CA15-3 concentrations demonstrated low-level predictive value (AUC=0.594, 0.644, 0.621, respectively). No significant differences in carcinoembryonic antigen (CEA) or CA12-5 serum levels were observed between the pCR and non-pCR groups (P=0.196 and 0.693, respectively). No efficient AUC of CEA or CA12-5 concentrations were observed to predict patient response toward neoadjuvant treatment (both less than 0.7), nor were differences between the two groups observed at different time points. We then analyzed the Her-2 positive subset of our cohort. Significant differences in CEA concentrations were identified between the pCR and non-pCR groups (P=0.039), but not in CA15-3 or CA12-5 levels (p=0.092 and 0.89, respectively). None of the ROC curves showed underlying prognostic value, as the AUCs of these three markers were less than 0.7. The ROC-AUCs for the CA12-5 concentrations of inter-and post-neoadjuvant chemotherapy in the estrogen receptor negative HER2 positive subgroup were 0.735 and 0.767, respectively. However, the specificity and sensitivity values were at odds with each other which meant that improving either the sensitivity or specificity would impair the efficiency of the other. CONCLUSIONS:Serum tumor markers CA15-3, CA12-5, and CEA might have little clinical significance in predicting neoadjuvant treatment response in locally advanced breast cancer.

Clinical value of neuroendocrine markers for neoadjuvant chemotherapy response in patients with non-small-cell lung cancer(NSCLC)

Clinical value of neuroendocrine differentiation markers and p53 in prognostic assessment of non small cell lung cancer

Research on the Relationship Between Non-small Cell Lung Cancer with Neuroendocrine Differentiation and the Biological Characteristics and Prognosis

The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Relationship Between ERCC1 Expression and Efficacy of Neoadjuvant Chemotherapy in the Patients with Non-Small-cell Lung Cancer

Neuroendocrine differentiation is not a malignant index of non-small cell lung cancer]

[Study on the Specific Expressions of P53, Bcl-2 and C-Myc in Non-Small Cell Lung Cancer with Neuroendocrine Differentiation].

Clinical evaluation of carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 and neuron-specific enolase in locally advanced-stage non-small cell lung cancer patients with adjuvant chemotherapy

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications

Extracellular matrix expression in non small cell lung cancer and its relationship with neo-adjuvant chemotherapy

Significance of circulating tumor cells combined with gastrin releasing peptide and neuron specific enolase levels in evaluating the efficacy of chemotherapy for patients with small cell lung cancer

Clinical Value of Serum Tumor Markers in Predicting Patients' Responses to Targeted Therapy for Advanced Non-Small Cell Lung Cancer

Clinical Value of CEA, CA125, CYFRA21-1, NSE and SCC for Evaluation of Chemotherapy Efficacy and Progression in Patients with Non-Small-cell Lung Cancer

Neuroendocrine Markers in Adenocarcinomas: an Investigation of 356 Cases.

Clinical Evaluation of Serum Tumor Markers in Patients with Advanced-Stage Non-Small Cell Lung Cancer Treated with Palliative Chemotherapy in China

[Predicting Efficacy of Neoadjuvant Cheomotherapy on Resectable Stage IIIA Non-Small Cell Lung Cancer by Multi-Gene Expressions].

Clinical value of NSE and CA125 as an indicator of assessing therapeutic efficacy in small cell lung cancer

Predictive value of serum NSE and Pro-GRP levels in patients with small cell lung cancer

[On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer]

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

[A clinicopathologic study on neoadjuvant chemotherapy in the treatment of non-small-cell lung cancer].